Clinical Trials Browser

Phase 3 × pyrotinib × 90 days × Clear all

NCT07615751 2026-05-29

Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer

Phase 3 Recruiting

Breast Neoplasms